CytomX Therapeutics (CTMX) Tops Q3 EPS by 23c

CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of $0.04, $0.23 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $26.38 million versus the consensus estimate of $13.34 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• Worried the AI trade has gone too far? Evercore likes these 4 stocks